Mirla Avila, MD, shares key monitoring considerations for patients receiving anti-CD20 therapies for MS, with a focus on infection risk and the potential influence of patient age.
Transcript
Anti-CD20s are among the most commonly prescribed medications now, even for newly diagnosed patients. Sometimes, we need to transition a patient from one drug to an anti-CD20. These medications are very effective, but they reduce B cells, which produce antibodies and have other functions in the immune system.
One thing we monitor is whether patients are having infections, or having them more often than before. Most patients tolerate these medications very well, so I don’t want you to think that infections are always a problem. What we monitor also depends a lot on the patient’s age. In general, the older the patient, the greater the risk of infection, so we may keep a closer eye on them.
Anti-CD20 medications are widely prescribed because they’re very effective at reducing relapses and new lesions on MRI.